Skip to content

Barbora Provaznikova

3 papers in the library · publishing 2025-2026

Papers

Sort Most recent Most cited

Esketamine for treatment-resistant depression: Comparing two maintenance schedules in an observational real-world study

Research Square July 9, 2026 Samuel Westenhöfer, Yamina Ehrt, Barbora Provaznikova et al.

Abstract Background : Treatment-resistant depression (TRD) is associated with substantial clinical and socioeconomic burden. Intranasal esketamine has shown efficacy for TRD in clinical trials and real-world studies. However, evidence on optimal maintenance scheduling is limited. We therefore investigated whether two maintenance schedules differing in their inter-dose intervals were associated...

Real-World Psilocybin Therapy for Treatment-Resistant Depression: a Retrospective Observational Study

December 10, 2025 Johannes Jungwirth, Samuel Westenhöfer, Helena Aicher et al.

Abstract Psilocybin has demonstrated promising antidepressant effects in depression and treatment-resistant depression (TRD) in controlled clinical trials. However, its effectiveness and safety in real-world therapeutic settings remain largely unknown. Although psilocybin is not yet approved as an antidepressant treatment, Switzerland’s unique legal framework allows its limited medical use for...

Inhalational nitrous oxide as a transdiagnostic approach for the treatment of suicidal ideation and suicidality in psychiatric inpatients: protocol for a double-blind randomised, controlled clinical single-centre trial.

BMJ Open July 16, 2025 Golo Kronenberg, Anna Bankwitz, Barbora Provaznikova et al.

Suicidal thoughts and behaviours are linked to a wide range of mental health conditions. New interest in the psychiatric benefits of nitrous oxide (N2O) has only recently emerged. The broad pharmacological effects of N2O are thought to be due in large part to N-methyl-d-aspartate antagonism and opioid effects. The purpose of this study protocol is to test whether inhalational N2O exerts rapid...